Patents by Inventor John M. Szabocsik

John M. Szabocsik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion
    Patent number: 9636355
    Abstract: An ophthalmic solution is provided. The ophthalmic solution is hypertonic. The ophthalmic solution includes a polysaccharide having an average molecular weight of between about 40,000 grams per mole and about 150,000 grams per mole. A packaged ophthalmic solution for preventing the ophthalmic solution from being exposed to CO2 and other contaminants is also provided. The ophthalmic solution can be used to treat recurrent corneal erosion. The ophthalmic solution can also be used as a prophylactic to prevent recurrent corneal erosion.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: May 2, 2017
    Assignee: Theo Holdings, LLC
    Inventor: John M. Szabocsik
  • Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion
    Patent number: 9351991
    Abstract: An ophthalmic solution is provided. The ophthalmic solution is hypertonic. The ophthalmic solution includes a polysaccharide having an average molecular weight of between about 40,000 grams per mole and about 150,000 grams per mole. A packaged ophthalmic solution for preventing the ophthalmic solution from being exposed to CO2 and other contaminants is also provided. The ophthalmic solution can be used to treat recurrent corneal erosion. The ophthalmic solution can also be used as a prophylactic to prevent recurrent corneal erosion.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: May 31, 2016
    Assignee: Theo Holdings, LLC
    Inventor: John M. Szabocsik
  • Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion
    Patent number: 9351990
    Abstract: An ophthalmic solution is provided. The ophthalmic solution is hypertonic. The ophthalmic solution includes a polysaccharide having an average molecular weight of between about 40,000 grams per mole and about 150,000 grams per mole. A packaged ophthalmic solution for preventing the ophthalmic solution from being exposed to CO2 and other contaminants is also provided. The ophthalmic solution can be used to treat recurrent corneal erosion. The ophthalmic solution can also be used as a prophylactic to prevent recurrent corneal erosion.
    Type: Grant
    Filed: August 16, 2013
    Date of Patent: May 31, 2016
    Assignee: Theo Holdings, LLC
    Inventor: John M. Szabocsik
  • Hypertonic Dextran Solution and Methods of Treating and Preventing Recurrent Corneal Erosion
    Publication number: 20140045786
    Abstract: An ophthalmic solution is provided. The ophthalmic solution is hypertonic. The ophthalmic solution includes a polysaccharide having an average molecular weight of between about 40,000 grams per mole and about 150,000 grams per mole. A packaged ophthalmic solution for preventing the ophthalmic solution from being exposed to CO2 and other contaminants is also provided. The ophthalmic solution can be used to treat recurrent corneal erosion. The ophthalmic solution can also be used as a prophylactic to prevent recurrent corneal erosion.
    Type: Application
    Filed: August 16, 2013
    Publication date: February 13, 2014
    Applicant: Theo Holdings, LLC
    Inventor: John M. Szabocsik
  • Hypertonic Dextran Solution and Methods of Treating and Preventing Recurrent Corneal Erosion
    Publication number: 20140045787
    Abstract: An ophthalmic solution is provided. The ophthalmic solution is hypertonic. The ophthalmic solution includes a polysaccharide having an average molecular weight of between about 40,000 grams per mole and about 150,000 grams per mole. A packaged ophthalmic solution for preventing the ophthalmic solution from being exposed to CO2 and other contaminants is also provided. The ophthalmic solution can be used to treat recurrent corneal erosion. The ophthalmic solution can also be used as a prophylactic to prevent recurrent corneal erosion.
    Type: Application
    Filed: August 16, 2013
    Publication date: February 13, 2014
    Applicant: Theo Holdings, LLC
    Inventor: John M. Szabocsik
  • Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion
    Publication number: 20130079301
    Abstract: An ophthalmic solution is provided. The ophthalmic solution is hypertonic. The ophthalmic solution includes a polysaccharide having an average molecular weight of between about 40,000 grams per mole and about 150,000 grams per mole. A packaged ophthalmic solution for preventing the ophthalmic solution from being exposed to CO2 and other contaminants is also provided. The ophthalmic solution can be used to treat recurrent corneal erosion. The ophthalmic solution can also be used as a prophylactic to prevent recurrent corneal erosion.
    Type: Application
    Filed: September 22, 2011
    Publication date: March 28, 2013
    Inventor: John M. Szabocsik